Moderna United States — Property, plant and equipment, net decreased by 4.2% to $1.47B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.2%, from $1.53B to $1.47B.
An increase typically signals significant capital expenditure for facility expansion or manufacturing capacity, while a decrease may reflect asset depreciation, divestitures, or a shift toward outsourced production models.
This metric represents the net book value of tangible long-term assets located within the United States, including manuf...
Biotech firms with internal manufacturing capabilities show higher levels of these assets compared to 'asset-light' companies that rely primarily on contract manufacturing organizations.
mrna_segment_united_states_property_plant_and_equipment_net| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.05B | $1.27B | $1.56B | $1.53B | $1.47B |
| QoQ Change | — | +20.7% | +23.1% | -1.8% | -4.2% |
| YoY Change | — | +20.7% | +23.1% | -1.8% | -4.2% |